Chemical biology & drug design最新文献

{"title":"MSC C1: A Potential Hub Linking Stromal Plasticity, Immune Regulation, and Patient Survival in Lung Adenocarcinoma.","authors":"Houlei Wang, Tianle Ma, Chao Jia, Chunhui Ma","doi":"10.1111/cbdd.70414","DOIUrl":"https://doi.org/10.1111/cbdd.70414","url":null,"abstract":"<p><p>Bone metastasis of lung adenocarcinoma (LUAD) directly leads to poor prognosis. This study aimed to dissect the stromal landscape of LUAD with bone metastases. Unsupervised clustering of scRNA-seq data from LUAD patients with bone metastasis identifies stromal subsets. Pseudotime analysis combined with CytoTRACE stemness scoring reconstructs mesenchymal stromal cell (MSC) differentiation trajectories, while CellChat characterizes cell-cell communication networks among MSC subpopulations. Differentially expressed genes (DEGs) specific to functionally distinct MSC subsets are subjected to LASSO-Cox regression for construction of a prognostic RiskScore model, which is validated in independent bulk RNA-seq cohorts regarding overall survival, immune cell infiltration, and drug sensitivity. A distinct high-stemness MSC C1 subpopulation is localized at the bifurcation point of two divergent differentiation trajectories toward a matrix-remodeling fate and a secretory, immunomodulatory phenotype. The RiskScore model stratifies patients into low- and high-risk groups with divergent overall-survival outcomes. Reduced infiltration of cytotoxic lymphocytes is observed in high-risk patients, and higher drug sensitivity within the high-risk subgroup. In vitro assays verify that LDHA knockdown impairs proliferation and migration in A549 cells. This study provides a rationale for targeting stroma-derived genes in risk-adapted therapy.</p>","PeriodicalId":93931,"journal":{"name":"Chemical biology & drug design","volume":"108 4","pages":"e70414"},"PeriodicalIF":3.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanism of Qianlie Zhitong Formula Against Chronic Prostatitis Based on Proteomics and Metabolomics.","authors":"Lidan Dong, Linhan Chang, Caijia Song, Jialin Yan, Tiantong Shen, Zhen Ding, Yunyu Liu, Chenglong Zheng, Yanfei Zheng, Qi Wang","doi":"10.1111/cbdd.70401","DOIUrl":"https://doi.org/10.1111/cbdd.70401","url":null,"abstract":"<p><p>Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent pelvic pain disorder in men, yet effective pharmacotherapies remain limited. Emerging evidence suggests that oxidative stress and dysregulated iron metabolism contribute to the pathogenesis of CP/CPPS, with ferroptosis increasingly implicated in CP/CPPS-related pathology. Qianlie Zhitong Formula (QLZTF) has shown therapeutic potential in treating CP/CPPS; however, its underlying mechanisms remain incompletely understood. This study integrated proteomics, metabolomics, and in vivo experiments to investigate the therapeutic mechanisms of QLZTF. A carrageenan-induced rat model was established, and rats were randomly assigned to five groups: control, model, Qianliekang, low-dose QLZTF, and high-dose QLZTF. QLZTF significantly reduced inflammatory cytokines (TNF-α, IL-6, and IL-1β), alleviated pain responses, and ameliorated prostate tissue injury. Proteomic analysis identified BCAT2, ALDH1B1, and ALDH2 as significantly upregulated proteins closely associated with ferroptosis. KEGG enrichment analysis of both proteomic and metabolomic data revealed that pantothenate and CoA biosynthesis and branched-chain amino acid (BCAA) degradation pathways were significantly enriched. Integrated analysis indicated that QLZTF synergistically regulates these pathways, activates the BCAT2/ALDH axis, and inhibits ferroptosis, thereby alleviating inflammation, pain, and fibrosis in CP/CPPS. This study provides the first multiomics evidence for the anti-ferroptotic mechanism of QLZTF.</p>","PeriodicalId":93931,"journal":{"name":"Chemical biology & drug design","volume":"108 4","pages":"e70401"},"PeriodicalIF":3.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin eQTL-Cerebrospinal Fluid Metabolites-Keloid Axis: An Integrative Multi-Omics Mediation Mendelian Randomization Study.","authors":"Jie Xu, Mengqi Bai, Tongyun Liu","doi":"10.1111/cbdd.70346","DOIUrl":"10.1111/cbdd.70346","url":null,"abstract":"<p><p>Keloids are fibroproliferative dermal disorders characterized by excessive extracellular matrix deposition and a strong tendency to recur, yet the mechanistic links between inherited genetic variation, molecular phenotypes and disease risk remain incompletely understood. We integrated GTEx v8 skin expression quantitative trait loci (eQTL) data, pooled GWAS statistics for 338 cerebrospinal fluid (CSF) metabolites, and two independent European keloid GWAS datasets within a three-step Mendelian randomization (MR) framework to identify causal mediation pathways from skin gene expression through systemic metabolite levels to keloid susceptibility. Bulk RNA-seq, single-cell RNA-seq and in vitro fibroblast and smooth muscle cell experiments were then used to validate the functional roles of the prioritized genes and metabolites. Four CSF metabolites-sphingomyelin, 1-stearoyl-2-oleoyl-glycerophosphocholine (SOPC), N-acetylarginine and X-23593-were causally associated with increased keloid risk (OR > 1) and replicated across both GWAS datasets. PARP14 emerged as a reproducible upstream risk gene (OR = 1.17, 95% CI 1.02-1.34) coordinating effects across all four mediators, whereas ALDH2 was identified as a SOPC-mediated protective gene (OR < 1). Single-cell profiling localized elevated PARP14 expression to smooth muscle cells and reduced ALDH2 expression to a disease-expanded mesenchymal fibroblast subset, with both signals embedded within canonical pro-fibrotic signaling programs (TGF-β, Wnt, Hippo, PI3K-Akt/mTOR, ECM-receptor interaction and focal adhesion). In vitro, SOPC and sphingomyelin produced dose-dependent fibroblast proliferation and induction of COL1A1, COL3A1, POSTN, and FN1, while modulation of PARP14 and ALDH2 by siRNA and lentiviral overexpression confirmed their roles in regulating proliferation and fibrotic marker expression. Together, these findings delineate a skin eQTL → CSF metabolite → cell-state axis in keloid pathogenesis, nominating PARP14, ALDH2 and SOPC-linked lipid remodeling as candidates for mechanistic study and therapeutic targeting.</p>","PeriodicalId":93931,"journal":{"name":"Chemical biology & drug design","volume":"107 6","pages":"e70346"},"PeriodicalIF":3.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148310911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Thiazolyl-Pyrazoline Derivatives as Potential EGFR Inhibitors.","authors":"Mayuri A Patil, Sachin S Bhusari, Pravin S Wakte","doi":"10.1111/cbdd.70345","DOIUrl":"10.1111/cbdd.70345","url":null,"abstract":"<p><p>A novel series of thiazolyl-pyrazoline derivatives (MAP-1 to MAP-20) was designed and synthesized as potential epidermal growth factor receptor (EGFR) inhibitors. The structures of all compounds were confirmed by ¹H NMR, ¹³C NMR, and HRMS analyses. The synthesized derivatives were evaluated for in vitro anticancer activity using the MTT assay against MCF-7 (breast), A549 (lung), HeLa (cervical), and non-tumorigenic MCF-10A cell lines. Among the tested compounds, MAP-13, MAP-15, and MAP-19 exhibited potent cytotoxic activity against MCF-7 (IC₅₀ = 1.09 ± 0.8, 2.33 ± 0.84, and 2.11 ± 0.26 μM, respectively), A549 (IC₅₀ = 2.06 ± 0.16, 2.81 ± 0.16, and 2.76 ± 0.42 μM, respectively), and HeLa cells (IC₅₀ = 1.18 ± 0.9, 2.27 ± 0.18, and 2.15 ± 0.36 μM, respectively), with improved selectivity over normal MCF-10A cells. Molecular docking studies against EGFR (PDB ID: 4I23) revealed strong binding affinities, with docking scores of -8.67, -9.31, and -9.00 kcal/mol for MAP-13, MAP-15, and MAP-19, respectively. Key interactions within the ATP-binding pocket suggested stable ligand-receptor complex formation. In silico ADMET profiling confirmed acceptable drug-likeness and pharmacokinetic properties for the lead compounds. These findings indicate that thiazolyl-pyrazoline hybrids represent promising scaffolds for the development of selective EGFR-targeted anticancer agents.</p>","PeriodicalId":93931,"journal":{"name":"Chemical biology & drug design","volume":"107 6","pages":"e70345"},"PeriodicalIF":3.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148310842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design, Synthesis, and In Vitro Biological Assessment of Novel Benzimidazole and Hydrazone Derivatives Against Pancreatic Cancer and Melanoma Cells.","authors":"Beyza Ecem Oz Bedir, Tuba Ozdemir Sanci, Emine Terzi, Elif Ercan, Nour El-Huda Daoud, Ulviye Acar Çevik","doi":"10.1111/cbdd.70349","DOIUrl":"https://doi.org/10.1111/cbdd.70349","url":null,"abstract":"<p><p>In this study, novel Benzimidazole-Hydrazone derivatives (5A-5J) were synthesized and evaluated for their in vitro anticancer activities against Panc-1, SK-MEL-30, HeLa, and BEAS-2B cell lines. WST-1 cytotoxicity assays revealed that compound 5A displayed notable potency in SK-MEL-30 cells (IC₅₀ = 23.25 ± 1.40 μM), whereas compound 5H exhibited significant cytotoxicity in Panc-1 cells (IC₅₀ = 27.6 ± 1.1 μM), with minimal effects on BEAS-2B cells (> 200 μM), suggesting a favorable in vitro safety profile under the tested conditions. Flow cytometric analyses demonstrated that 5A and 5H induced apoptosis and enhanced the apoptotic response when combined with Cisplatin, increasing apoptotic rates up to 80% in SK-MEL-30 and 90% in Panc-1 cells, respectively. Cell cycle analysis revealed that compound 5A induced G1 arrest in SK-MEL-30 cells, while compound 5H caused G2/M arrest in Panc-1 cells. Wound healing assays further confirmed the antimigratory potential of both compounds, alone and in combination with Cisplatin. In silico ADMET profiling provided preliminary insights into the pharmacokinetic properties of compounds 5A and 5H, indicating generally acceptable drug-likeness parameters within the limitations of computational prediction. Molecular docking analyses suggested potential interactions with the caspase-3 active site; however, these findings should be interpreted as supportive computational observations and do not provide direct evidence of a specific molecular mechanism underlying the observed apoptotic effects. These findings indicated that compounds 5A and 5H exhibited notable in vitro anticancer activity and may serve as potential candidates for further investigation.</p>","PeriodicalId":93931,"journal":{"name":"Chemical biology & drug design","volume":"107 6","pages":"e70349"},"PeriodicalIF":3.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148341414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design, Optimization and Mechanistic Insights Into Terpenoid-Derived Inhibitors of Protein Kinase C Iota.","authors":"Rachid Chahboun, Fernando Rodríguez-Serrano, Ángel Bueno, Nuria Mut-Salud, Ramón Alvarez-Manzaneda, Enrique Alvarez-Manzaneda, Antonio Fernández","doi":"10.1111/cbdd.70348","DOIUrl":"10.1111/cbdd.70348","url":null,"abstract":"<p><p>Protein kinase C iota (PKCι) is an atypical PKC isoform overexpressed in several human cancers and associated with tumor initiation, maintenance, and resistance to therapy. Meroxest, a synthetic naphthoquinone merosesquiterpene previously shown to exert antitumor activity in breast cancer models, has an incompletely defined mechanism of action. Here, we profiled meroxest against a 410-kinase panel and synthesized a focused set of analogues to obtain preliminary PKCι-oriented structure-activity information. At 10 μM, meroxest reduced PKCι enzymatic activity to 52% of control and Cdc7/cyclin B1 activity to 63%, identifying PKCι as the most inhibited kinase in the panel while also indicating that additional kinase targets may contribute to the biological activity of this scaffold. Docking studies supported a plausible interaction of meroxest within the PKCι catalytic site, including hydrogen-bond contacts with Gly398 and Phe423 consistent with an ATP-competitive binding mode. Biochemical evaluation of a focused library against PKCι at 10 μM showed that preservation of the quinone framework was important for activity, whereas most structural modifications produced only limited changes under the assay conditions used. Compound 19, lacking the methyl substituent on the naphthoquinone ring, showed a modest improvement relative to meroxest. Overall, these results support PKCι as a leading candidate target emerging from the meroxest kinase profile and identify compound 19 as a scaffold for further optimization. Future studies will focus on further optimization to improve the modest PKCι inhibitory potency, evaluate activity against Cdc7/cyclin B1 beyond the parent compound, and validate target engagement in cell-based assays, aiming to identify optimal candidates.</p>","PeriodicalId":93931,"journal":{"name":"Chemical biology & drug design","volume":"107 6","pages":"e70348"},"PeriodicalIF":3.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13307258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148341433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Associations Between Dietary Flavonoid Intake and Neurodegenerative Diseases Risk: A Cross-Sectional Study.","authors":"Chenzhong Zong, Yang Dong, Xue Yu, Yu He, Xiaoqing Zhang, Kuo Gao","doi":"10.1111/cbdd.70350","DOIUrl":"10.1111/cbdd.70350","url":null,"abstract":"<p><p>The incidence of neurodegenerative diseases (NDs), primarily Alzheimer's disease and Parkinson's disease, has been steadily increasing, constituting a significant global public health challenge. This study aims to evaluate the associations between dietary flavonoid intake and the risk of NDs. Data from 13,573 participants in the National Health and Nutrition Examination Survey (NHANES) were analyzed. Weighted logistic regression, receiver operating characteristic (ROC) curve analysis, weighted restricted cubic splines, subgroup analysis, and sensitivity analysis were employed to assess the associations. Overall, higher total flavonoid intake was associated with lower odds of NDs after adjustment for demographic, socioeconomic, lifestyle, and clinical covariates (Q4 vs. Q1: OR = 0.52, 95% CI: 0.31-0.90). Among flavonoid subclasses, flavones (Q4 vs. Q1: OR = 0.49, 95% CI: 0.30-0.79) and flavonols (Q4 vs. Q1: OR = 0.53, 95% CI: 0.33-0.86) showed the strongest inverse associations. In addition, restricted cubic spline analyses demonstrated significant non-linear relationships, with the lowest odds of NDs observed at intake levels of approximately 432 mg/day for total flavonoids, 1.7 mg/day for flavones, and 29 mg/day for flavonols. These findings suggest that moderate intake of flavonoids, particularly flavones and flavonols, may contribute to the observed inverse association between flavonoid intake and NDs.</p>","PeriodicalId":93931,"journal":{"name":"Chemical biology & drug design","volume":"107 6","pages":"e70350"},"PeriodicalIF":3.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13291634/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148310846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"An AI-Guided Structure-Based Strategy for the Discovery and Biological Validation of Natural Products Targeting the Vitamin D Receptor From YSQYP in Diabetic Kidney Disease\".","authors":"","doi":"10.1111/cbdd.70303","DOIUrl":"10.1111/cbdd.70303","url":null,"abstract":"","PeriodicalId":93931,"journal":{"name":"Chemical biology & drug design","volume":"107 5","pages":"e70303"},"PeriodicalIF":3.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147936317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peptides as a Therapeutic Alternative Against Leishmaniasis: A Scoping Review.","authors":"Maria Eduarda da Veiga Oliveira, Ellen Dyminski Parente Ribeiro, Otávio Henrique Pradi Guenther, Fernanda Tomiotto-Pellissier","doi":"10.1111/cbdd.70314","DOIUrl":"10.1111/cbdd.70314","url":null,"abstract":"<p><p>Leishmaniasis is a neglected tropical disease with high global health and socioeconomic burden, particularly in low-income regions where current treatments remain limited by high toxicity, cost, and increasing resistance. Antimicrobial peptides (AMPs), small bioactive molecules with broad-spectrum activity and low propensity for resistance, have emerged as promising therapeutic candidates. This scoping review aimed to map the existing literature on AMPs with anti-leishmanial activity, updating and expanding upon previous reviews. Following the PRISMA-ScR framework, we systematically searched for primary research articles assessing natural and synthetic peptides through in vitro or in vivo approaches. Seventy-nine studies met eligibility criteria, evaluating 231 unique peptides against multiple Leishmania species. Most investigations were in vitro, particularly on L. major promastigotes and amastigotes. Synthetic and bioengineered peptides demonstrated superior efficacy and selectivity compared with natural peptides, in some cases achieving selectivity indices exceeding 6000. Mechanistic studies revealed that AMPs act primarily through parasite membrane disruption, but also by inducing apoptosis-like processes and modulating host immune responses. Despite their promise, several challenges remain, including peptide instability in physiological conditions, proteolytic degradation, and limited in vivo validation. Advances in chemical modifications and nanocarrier-based delivery systems show potential to overcome these barriers. In conclusion, AMPs represent a compelling avenue for leishmaniasis therapy, especially for cutaneous forms of the disease. However, further studies, particularly in vivo, are critical to translate preclinical findings into clinical application.</p>","PeriodicalId":93931,"journal":{"name":"Chemical biology & drug design","volume":"107 5","pages":"e70314"},"PeriodicalIF":3.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13184368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147977882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polycationic Peptides That Bind T-Box Riboswitch Antiterminator RNA and Inhibit Riboswitch Function.","authors":"Emily Fairchild, Danushika Herath, Sebastian Lux, Sophie R Harvey, Deborah Amesaki, Destini McCartney, Monique Richter, Ralf Hoffmann, Jennifer V Hines","doi":"10.1111/cbdd.70312","DOIUrl":"10.1111/cbdd.70312","url":null,"abstract":"<p><p>Resistance to antibiotic treatments continues to be a significant health challenge and necessitates investigating novel antibacterial targets including noncoding regulatory RNA. The antiterminator RNA element of the T-box riboswitch is one such novel target. In this report, we investigated a spatially dispersed polycationic pharmacophore model for targeting the T-box antiterminator RNA. Decapeptides were designed based on a known alkyl polyamine agonist of the T-box riboswitch. Antiterminator model RNA binding was assessed using native mass spectrometry and modulation of T-box riboswitch function determined using a previously validated fluorescence-based assay. One peptide was identified that formed a complex with antiterminator model RNA and selectively inhibited T-box riboswitch transcription readthrough (both with and without tRNA induction). The inhibitory activity of this polycationic peptide, which was designed to mimic biogenic polyamines, has implications for future drug discovery efforts targeting the T-box riboswitch and other medicinally important noncoding regulatory RNA.</p>","PeriodicalId":93931,"journal":{"name":"Chemical biology & drug design","volume":"107 5","pages":"e70312"},"PeriodicalIF":3.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13158646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147870851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}